Interferon-γ-induced p27KIP1 binds to and targets MYC for proteasome-mediated degradation

Area of Science:

• Cellular Biology
• Oncology
• Molecular Mechanisms of Cancer

Background:

• The Myc oncoprotein is a key regulator of cell proliferation, survival, and metabolism, and its dysregulation is common in cancer.
• Myc activity is tightly controlled through various mechanisms, including ubiquitin-mediated protein degradation.
• Previous research indicated that Cdk2-mediated phosphorylation of Myc at Ser-62 influences its activity and that p27(Kip1) (p27) can repress Myc activity.

Purpose of the Study:

• To investigate the role of p27 in regulating Myc turnover, independent of Myc's Ser-62 phosphorylation.
• To elucidate the molecular mechanism by which p27 interacts with and promotes Myc degradation.
• To explore the clinical relevance of the p27-Myc interaction in breast cancer.

Main Methods:

• Investigated the interaction between p27 and Myc using co-immunoprecipitation and immunofluorescence assays.
• Assessed Myc degradation upon p27 expression and identified the functional domains of p27 involved in Myc interaction.
• Analyzed protein expression data from The Cancer Genome Atlas (TCGA) breast invasive carcinoma cohort to correlate p27 and Myc levels with clinical parameters.

Main Results:

• Identified a novel mechanism where p27 directly induces Myc degradation, independent of Myc's Ser-62 phosphorylation.
• Demonstrated that p27 interacts with Myc in the nucleus, involving their C-terminal regions, including Myc box 4.
• Showed that highly expressed p27, specifically the nuclear-localized, non-phosphorylated form (at Thr-157), is associated with lower Myc protein levels in breast tumors.
• Observed that these conditions (high p27, low Myc) correlate with favorable tumor stage and patient outcomes.

Conclusions:

• p27(Kip1) acts as a direct negative regulator of Myc oncoprotein stability through nuclear interaction and subsequent degradation.
• This interferon-gamma (IFN-γ)-mediated pathway involving p27 provides a novel mechanism for controlling Myc activity.
• The findings suggest that targeting the p27-Myc axis could represent a potential therapeutic strategy for Myc-driven cancers, particularly those with specific p27 phosphorylation states.